Yüklüyor......
Optimizing biologic treatment in IBD: objective measures, but when, how and how often?
BACKGROUND: The advent of biologic agents for the treatment of inflammatory bowel disease (IBD) was accompanied in parallel with emerging understanding of persisting underlying inflammation and ensuing bowel damage that can occur even in patients with seeming clinical remission. This lead to the con...
Kaydedildi:
| Yayımlandı: | BMC Gastroenterol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4683713/ https://ncbi.nlm.nih.gov/pubmed/26678147 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-015-0408-x |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|